2018-2023 Global RNAi for Therapeutic Market Report (Status and Outlook)

2018-2023 Global RNAi for Therapeutic Market Report (Status and Outlook)

In this report, LP Information studies the present scenario (with the base year being 2017) and the growth prospects of global RNAi for Therapeutic market for 2018-2023. RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression. RNAi for Therapeutic is in the development stage and there is no use in the market. The fastest research is Clinical phrase III, Such as QP1-1007, QO1-1002 of Quark Pharmaceuticals. The major technology of RNAi for Therapeutic is siRNA, miRNA and shRNA. SiRNA technology is the most popular, with the expenses market share of 85%, following SiRNA, miRNA is the second of 16% expenses market share in 2015. At present, global expenses concentrates in US and Europe, US takes 80% market share and Europe takes 5% market share. There is A Few R & D Company in the world and the market concentration is high. The top5 (expenses in RNAi for Therapeutic) companies are Alnylam Pharmaceuticals, Arrowhead, Dicerna Pharmaceuticals, Gradalis, miRagen Therapeutics. The five companies occupy about 83% of the market share. Over the next five years, LPI(LP Information) projects that RNAi for Therapeutic will register a 24.0% CAGR in terms of revenue, reach US$ 3580 million by 2023, from US$ 990 million in 2017. This report presents a comprehensive overview, market shares and growth opportunities of RNAi for Therapeutic market by product type, application, key companies and key regions. To calculate the market size, LP Information considers value generated from the sales of the following segments: Segmentation by product type: siRNA miRNA Segmentation by application: Cancer Cardiovascular HBV Other We can also provide the customized separate regional or country-level reports, for the following regions: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Spain Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Alnylam Pharmaceuticals Arbutus Biopharma (Tekmira) Arrowhead Dicerna Pharmaceuticals Mirna Therapeutics Quark Pharmaceuticals RXi Pharmaceuticals Silence Therapeutics Benitec Biopharma miRagen Therapeutics Sylentis Gradalis Sirnaomics Silenseed In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development. Research objectives To study and analyze the global RNAi for Therapeutic market size by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023. To understand the structure of RNAi for Therapeutic market by identifying its various subsegments. Focuses on the key global RNAi for Therapeutic players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze the RNAi for Therapeutic with respect to individual growth trends, future prospects, and their contribution to the total market. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). To project the size of RNAi for Therapeutic submarkets, with respect to key regions (along with their respective key countries). To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market. To strategically profile the key players and comprehensively analyze their growth strategies.
Table of Contents 2018-2023 Global RNAi for Therapeutic Market Report (Status and Outlook) 1 Scope of the Report 1.1 Market Introduction 1.2 Research Objectives 1.3 Years Considered 1.4 Market Research Methodology 1.5 Economic Indicators 1.6 Currency Considered 2 Executive Summary 2.1 World Market Overview 2.1.1 Global RNAi for Therapeutic Market Size 2013-2023 2.1.2 RNAi for Therapeutic Market Size CAGR by Region 2.2 RNAi for Therapeutic Segment by Type 2.2.1 siRNA 2.2.2 miRNA 2.2.3 shRNA 2.3 RNAi for Therapeutic Market Size by Type 2.3.1 Global RNAi for Therapeutic Market Size Market Share by Type (2013- 2018) 2.3.2 Global RNAi for Therapeutic Market Size Growth Rate by Type (2013-2018) 2.4 RNAi for Therapeutic Segment by Application 2.4.1 Cancer 2.4.2 Cardiovascular 2.4.3 HBV 2.4.4 Other 2.5 RNAi for Therapeutic Market Size by Application 2.5.1 Global RNAi for Therapeutic Market Size Market Share by Application (2013-2018) 2.5.2 Global RNAi for Therapeutic Market Size Growth Rate by Application (2013-2018) 3 Global RNAi for Therapeutic by Players 3.1 Global RNAi for Therapeutic Market Size Market Share by Players 3.1.1 Global RNAi for Therapeutic Market Size by Players (2016-2018) 3.1.2 Global RNAi for Therapeutic Market Size Market Share by Players (2016-2018) 3.2 Global RNAi for Therapeutic Key Players Head office and Products Offered 3.3 Market Concentration Rate Analysis 3.3.1 Competition Landscape Analysis 3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018) 3.4 New Products and Potential Entrants 3.5 Mergers & Acquisitions, Expansion 4 RNAi for Therapeutic by Regions 4.1 RNAi for Therapeutic Market Size by Regions 4.2 Americas RNAi for Therapeutic Market Size Growth 4.3 APAC RNAi for Therapeutic Market Size Growth 4.4 Europe RNAi for Therapeutic Market Size Growth 4.5 Middle East & Africa RNAi for Therapeutic Market Size Growth 5 Americas 5.1 Americas RNAi for Therapeutic Market Size by Countries 5.2 Americas RNAi for Therapeutic Market Size by Type 5.3 Americas RNAi for Therapeutic Market Size by Application 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Key Economic Indicators of Few Americas Countries 6 APAC 6.1 APAC RNAi for Therapeutic Market Size by Countries 6.2 APAC RNAi for Therapeutic Market Size by Type 6.3 APAC RNAi for Therapeutic Market Size by Application 6.4 China 6.5 Japan 6.6 Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 Key Economic Indicators of Few APAC Countries 7 Europe 7.1 Europe RNAi for Therapeutic by Countries 7.2 Europe RNAi for Therapeutic Market Size by Type 7.3 Europe RNAi for Therapeutic Market Size by Application 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 7.9 Spain 7.10 Key Economic Indicators of Few Europe Countries 8 Middle East & Africa 8.1 Middle East & Africa RNAi for Therapeutic by Countries 8.2 Middle East & Africa RNAi for Therapeutic Market Size by Type 8.3 Middle East & Africa RNAi for Therapeutic Market Size by Application 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers and Impact 9.1.1 Growing Demand from Key Regions 9.1.2 Growing Demand from Key Applications and Potential Industries 9.2 Market Challenges and Impact 9.3 Market Trends 10 Global RNAi for Therapeutic Market Forecast 10.1 Global RNAi for Therapeutic Market Size Forecast (2018-2023) 10.2 Global RNAi for Therapeutic Forecast by Regions 10.2.1 Global RNAi for Therapeutic Forecast by Regions (2018-2023) 10.2.2 Americas Market Forecast 10.2.3 APAC Market Forecast 10.2.4 Europe Market Forecast 10.2.5 Middle East & Africa Market Forecast 10.3 Americas Forecast by Countries 10.3.1 United States Market Forecast 10.3.2 Canada Market Forecast 10.3.3 Mexico Market Forecast 10.3.4 Brazil Market Forecast 10.4 APAC Forecast by Countries 10.4.1 China Market Forecast 10.4.2 Japan Market Forecast 10.4.3 Korea Market Forecast 10.4.4 Southeast Asia Market Forecast 10.4.5 India Market Forecast 10.4.6 Australia Market Forecast 10.5 Europe Forecast by Countries 10.5.1 Germany Market Forecast 10.5.2 France Market Forecast 10.5.3 UK Market Forecast 10.5.4 Italy Market Forecast 10.5.5 Russia Market Forecast 10.5.6 Spain Market Forecast 10.6 Middle East & Africa Forecast by Countries 10.6.1 Egypt Market Forecast 10.6.2 South Africa Market Forecast 10.6.3 Israel Market Forecast 10.6.4 Turkey Market Forecast 10.6.5 GCC Countries Market Forecast 10.7 Global RNAi for Therapeutic Forecast by Type 10.8 Global RNAi for Therapeutic Forecast by Application 11 Key Players Analysis 11.1 Alnylam Pharmaceuticals 11.1.1 Company Details 11.1.2 RNAi for Therapeutic Product Offered 11.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2016-2018) 11.1.4 Main Business Overview 11.1.5 Alnylam Pharmaceuticals News 11.2 Arbutus Biopharma (Tekmira) 11.2.1 Company Details 11.2.2 RNAi for Therapeutic Product Offered 11.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue, Gross Margin and Market Share (2016-2018) 11.2.4 Main Business Overview 11.2.5 Arbutus Biopharma (Tekmira) News 11.3 Arrowhead 11.3.1 Company Details 11.3.2 RNAi for Therapeutic Product Offered 11.3.3 Arrowhead RNAi for Therapeutic Revenue, Gross Margin and Market Share (2016-2018) 11.3.4 Main Business Overview 11.3.5 Arrowhead News 11.4 Dicerna Pharmaceuticals 11.4.1 Company Details 11.4.2 RNAi for Therapeutic Product Offered 11.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2016-2018) 11.4.4 Main Business Overview 11.4.5 Dicerna Pharmaceuticals News 11.5 Mirna Therapeutics 11.5.1 Company Details 11.5.2 RNAi for Therapeutic Product Offered 11.5.3 Mirna Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2016-2018) 11.5.4 Main Business Overview 11.5.5 Mirna Therapeutics News 11.6 Quark Pharmaceuticals 11.6.1 Company Details 11.6.2 RNAi for Therapeutic Product Offered 11.6.3 Quark Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2016-2018) 11.6.4 Main Business Overview 11.6.5 Quark Pharmaceuticals News 11.7 RXi Pharmaceuticals 11.7.1 Company Details 11.7.2 RNAi for Therapeutic Product Offered 11.7.3 RXi Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2016-2018) 11.7.4 Main Business Overview 11.7.5 RXi Pharmaceuticals News 11.8 Silence Therapeutics 11.8.1 Company Details 11.8.2 RNAi for Therapeutic Product Offered 11.8.3 Silence Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2016-2018) 11.8.4 Main Business Overview 11.8.5 Silence Therapeutics News 11.9 Benitec Biopharma 11.9.1 Company Details 11.9.2 RNAi for Therapeutic Product Offered 11.9.3 Benitec Biopharma RNAi for Therapeutic Revenue, Gross Margin and Market Share (2016-2018) 11.9.4 Main Business Overview 11.9.5 Benitec Biopharma News 11.10 miRagen Therapeutics 11.10.1 Company Details 11.10.2 RNAi for Therapeutic Product Offered 11.10.3 miRagen Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2016-2018) 11.10.4 Main Business Overview 11.10.5 miRagen Therapeutics News 11.11 Sylentis 11.12 Gradalis 11.13 Sirnaomics 11.14 Silenseed 12 Research Findings and Conclusion

Inquiry Before Buying

Name*

Email*

Phone*

Name of the Company*

Title/ Designation*

Select Country*

How can we help you?*

Click Here

Request Sample

Name*

Email*

Phone*

Name of the Company*

Title/ Designation*

Select Country*

How can we help you?*


Related Reports

  • $ 4660
  • $ 6990
  • $ 9320
Report ID 131348
Category
Published On 2018-06-09
No. of Pages 136
Publisher Name